B12 Injection
US$ 26.27
fda statement bpc-157 compounding safety risks BPC 157 Dosage: A Doctor's Evidence-Based Guide Emerging Peptide Therapies in Orthopaedics:
Description
Peptide therapy with DAC is an exception, with a half-life of approximately 68 days, allowing for less frequent dosing
PMID 10554220
The good news is that the fatigue usually recedes by 12 weeks on the medication
Duration of treatment varies based on condition severity and individual response
The peptide also does not stimulate IGF-1 production, avoiding the growth-promoting and potentially mitogenic effects associated with IGF-1 elevation
